"Apolipoproteins E" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of protein components which can be found in several lipoproteins including HIGH-DENSITY LIPOPROTEINS; VERY-LOW-DENSITY LIPOPROTEINS; and CHYLOMICRONS. Synthesized in most organs, Apo E is important in the global transport of lipids and cholesterol throughout the body. Apo E is also a ligand for LDL receptors (RECEPTORS, LDL) that mediates the binding, internalization, and catabolism of lipoprotein particles in cells. There are several allelic isoforms (such as E2, E3, and E4). Deficiency or defects in Apo E are causes of HYPERLIPOPROTEINEMIA TYPE III.
| Descriptor ID |
D001057
|
| MeSH Number(s) |
D10.532.091.500 D12.776.070.400.500 D12.776.521.120.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Apolipoproteins E".
Below are MeSH descriptors whose meaning is more specific than "Apolipoproteins E".
This graph shows the total number of publications written about "Apolipoproteins E" by people in this website by year, and whether "Apolipoproteins E" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 0 | 2 |
| 1996 | 2 | 1 | 3 |
| 1999 | 1 | 2 | 3 |
| 2000 | 5 | 2 | 7 |
| 2001 | 3 | 2 | 5 |
| 2002 | 5 | 2 | 7 |
| 2003 | 3 | 0 | 3 |
| 2004 | 4 | 2 | 6 |
| 2005 | 8 | 1 | 9 |
| 2006 | 2 | 3 | 5 |
| 2007 | 1 | 1 | 2 |
| 2008 | 1 | 3 | 4 |
| 2009 | 2 | 8 | 10 |
| 2010 | 2 | 3 | 5 |
| 2011 | 4 | 4 | 8 |
| 2012 | 2 | 4 | 6 |
| 2013 | 4 | 7 | 11 |
| 2014 | 0 | 7 | 7 |
| 2015 | 2 | 5 | 7 |
| 2016 | 0 | 6 | 6 |
| 2017 | 2 | 4 | 6 |
| 2018 | 2 | 1 | 3 |
| 2020 | 0 | 1 | 1 |
| 2021 | 3 | 4 | 7 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 4 | 4 |
| 2024 | 1 | 2 | 3 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Apolipoproteins E" by people in Profiles.
-
Assessing the cardioprotective effects of exercise in APOE mouse models using deep learning and photon-counting micro-CT. PLoS One. 2025; 20(4):e0320892.
-
Association of common and rare variants with Alzheimer's disease in more than 13,000 diverse individuals with whole-genome sequencing from the Alzheimer's Disease Sequencing Project. Alzheimers Dement. 2024 Dec; 20(12):8470-8483.
-
APOE loss of function: A genetic shield against Alzheimer's disease. Neuron. 2024 Apr 03; 112(7):1033-1035.
-
Antisense oligonucleotide targeting hepatic Serum Amyloid A limits the progression of angiotensin II-induced abdominal aortic aneurysm formation. Atherosclerosis. 2024 04; 391:117492.
-
Impact of Apolipoprotein E Genotype on Neurocognitive Function in Patients With Brain Metastases: An Analysis of NRG Oncology's RTOG 0614. Int J Radiat Oncol Biol Phys. 2024 Jul 01; 119(3):846-857.
-
Advanced photon counting CT imaging pipeline for cardiac phenotyping of apolipoprotein E mouse models. PLoS One. 2023; 18(10):e0291733.
-
Large-scale whole exome sequencing studies identify two genes,CTSL and APOE, associated with lung cancer. PLoS Genet. 2023 09; 19(9):e1010902.
-
Behavioral and biologic characteristics of cancer-related cognitive impairment biotypes. Brain Imaging Behav. 2023 Jun; 17(3):320-328.
-
Serum amyloid A augments the atherogenic effects of cholesteryl ester transfer protein. J Lipid Res. 2023 05; 64(5):100365.
-
Mitochondria-targeted esculetin mitigates atherosclerosis in the setting of aging via the modulation of SIRT1-mediated vascular cell senescence and mitochondrial function in Apoe-/- mice. Atherosclerosis. 2022 09; 356:28-40.